Introduction - including what is CML and CIP2A. Methods 0 Patient characteristics table. Definitions of overall survival and progression free survival. 0 Statistical tests. Results - Analysis and interpretation of results 0 Figure 1 Kaplan Meier plots for overall survival A. Overall survival for lucasinib and vertinib B. Overall survival for CIP2A C. Overall survival for lucasinib with patients stratified by CIP2A D. Overall survival for vertinib with patients stratified by CIP2A o Figure 2 Kaplan Meier plots progression-free survival A. Progression-free survival for lucasinib and vertinib B. Progression-free survival for CIP2A C. Progression-free survival for lucasinib with patients stratified by CIP2A D. Progression-free survival for vertinib with patients stratified by CIP2A Discussion References - Referencing for this article should be in the format of the journal Blood. References are numbered in the text.13 A few examples are shown below. You can download the style add-in for end